Emergent’s application for its Narcan product to be sold OTC for the treatment of opioid overdose has been accepted by the US FDA and provided priority review.
The company’s Precision Olfactory Delivery technology, currently combined with its Trudhesa migraine treatment, reportedly facilitates high absorption rates.
Ena Respiratory’s preventative nasal spray treatment could reach human trials within four months, following results from an animal study released today which showed the spray reduced COVID-19 replication by up to 96%.
Nastech missed out on a $15m (€11m) milestone payment after having
to delay the development of its new nasal spray for the treatment
of osteoporosis because of the need of an additional clinical
trial.
UK-based Malvern Instruments has revealed that its next-generation
particle size analysis system is being used by French contract
manufacturer Valois in the validation of its unique nasal spray
device.
Nastech has secured a contract with Procter & Gamble (P&G)
to ramp up manufacturing capacity for a new needle-free drug to
beat osteoporosis, in anticipation of meeting expected global
demand once the product is approved.
Biotechnology firm Nastech has chosen Procter & Gamble to
develop and commercialise its osteoporosis nasal spray worldwide,
in a lucrative deal that could reach $577m (€480m) over the life of
the project and give both companies...
